Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 6/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | CSK | P41240 | 1/20 | 0.30 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10255747 | 0.91 | CYP2C8 (0.36) | AGTR1AGTR2CYP2C8ACKR3MAPT | |
| SCHEMBL10264023 | 0.91 | CYP2C8 (0.36) | AGTR1AGTR2CYP2C8MAPTTP53 | |
| SCHEMBL831551 | 0.88 | SCN9A (0.40) | CYP2C8SCN5ASCN9A | |
| SCHEMBL831683 | 0.88 | CYP2C8 (0.38) | CYP2C8SCN5ASCN9A | |
| SCHEMBL832356 | 0.87 | CYP2C8 (0.40) | AGTR1AGTR2CYP2C8SCN5ASCN9A | |
| SCHEMBL832400 | 0.87 | CYP2C8 (0.35) | CYP2C8MAPTTP53SCN5ASCN9A | |
| SCHEMBL831751 | 0.86 | CYP2C8 (0.41) | AGTR1AGTR2CYP2C8MAPTTP53 | |
| SCHEMBL831639 | 0.86 | CYP2C8 (0.37) | CYP2C8TP53RORCSCN5ASCN9A | |
| SCHEMBL831325 | 0.85 | CYP2C8 (0.37) | CYP2C8MAPTTP53SCN5ASCN9A | |
| SCHEMBL831983 | 0.85 | CYP2C8 (0.37) | CYP2C8SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | AGTR1 1013/4885AGTR2 350/4885CYP2C8 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.